Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06333678 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study Comparing Sotorasib With Durvalumab in People With Non-Small Cell Lung Cancer (NSCLC)

Name: A Study Comparing Sotorasib With Durvalumab in People With Non-Small Cell Lung Cancer (NSCLC) — clinical trial record (NCT06333678)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusTerminated

PhasePhase 2

SponsorMemorial Sloan Kettering Cancer Center

Started2024-03-20

View on ClinicalTrials.gov ↗

In this study, the researchers will look at whether having participants switch from durvalumab to sotorasib when they have detectable minimal residual disease (MRD) is an effective treatment approach for locally advanced non-small cell lung cancer (LA-NSCLC). The researchers will see whether this switch to sotorasib can control LANSCLC longer compared to the treatment approach of staying on durvalumab (and not switching to sotorasib).

Amendment history 2 changes detected by DataLookout

2026-09-03

Reclassified as terminated (was completed)

2026-09-03

Trial terminated: Study closed by Amgen due to lack of enrollment

Trial Details

NCT Number	NCT06333678
Lead Sponsor	Memorial Sloan Kettering Cancer Center Collaborators: Amgen
Conditions	Non-Small Cell Lung Cancer
Enrollment	10 participants
Start Date	2024-03-20
Primary Completion	2026-01-27 (estimated)
Study Completion	2026-01-27 (estimated)
Updated on ClinicalTrials.gov	2026-09-02